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Abstract
Introduction: Beta-blockers have cardioprotective, metabolic and immunomodulating effects that may be
beneficial to patients in intensive care. We examined the association between preadmission beta-blocker use and
30-day mortality following intensive care.
Methods: We identified 8,087 patients over age 45 admitted to one of three multidisciplinary intensive care units
(ICUs) between 1999 and 2005. Data on the use of beta-blockers and medications, diagnosis, comorbidities,
surgery, markers of socioeconomic status, laboratory tests upon ICU admission, and complete follow-up for
mortality were obtained from medical databases. We computed probability of death within 30 days following ICU
admission for beta-blocker users and non-users, and the odds ratio (OR) of death as a measure of relative risk using
conditional logistic regression and also did a propensity score-matched analysis.
Results: Inclusion of all 8,087 ICU patients in a logistic regression analysis yielded an adjusted OR of 0.82 (95%
confidence interval (CI): 0.71 to 0.94) for beta-blocker users compared with non-users. In the propensity score-
matched analysis we matched all 1,556 beta-blocker users (19.2% of the entire cohort) with 1,556 non-users; the
30-day mortality was 25.7% among beta-blocker users and 31.4% among non-users (OR 0.74 (95% CI: 0.63 to 0.87)].
The OR was 0.69 (95% CI: 0.54 to 0.88) for surgical ICU patients and 0.71 (95% CI: 0.51 to 0.98) for medical ICU
patients. The OR was 0.99 (95% CI: 0.67 to 1.47) among users of non-selective beta-blockers, and 0.70 (95% CI: 0.58
to 0.83) among users of cardioselective beta-blockers.
Conclusions: Preadmission beta-blocker use is associated with reduced mortality following ICU admission.
Introduction
Beta-blockers are used widely to treat cardiovascular
diseases and have been shown to reduce re-infarction
rates and mortality following myocardial infarction [1,2].
In patients with chronic heart failure, beta-blockers
improve cardiac function and reduce mortality [3,4].
Results from observational studies and randomized con-
trolled trials suggest that beta-blockers may reduce the
risk of perioperative cardiac complications and mortality
in high-risk patients undergoing major surgery, although
this has recently been challenged [5-12].
During critical illness, the whole body’s metabolism
shifts towards a hypermetabolic state, primarily in terms
of increased resting energy expenditure, rapid muscle
loss and hyperglycemia [13-15]. This metabolic shift is
mediated mainly through a catecholamine surge and
sympathetic activation during the early phase of critical
illness [16]. Attenuation of the hypermetabolic state has
been associated with reduced mortality [16-18]. For
instance, blocking of the beta-adrenergic stimulation of
the catecholamine surge has been suggested as the
underlying biological mechanism for the reduced mor-
tality observed in beta-blocker users hospitalized with
severe trauma and burns [18-21].
Most ICU patients also have varying degrees of the sys-
temic inflammatory response syndrome. Key mediators of
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the cellular immune system have beta-adrenergic recep-
tors [22,23], and in vitro studies have suggested a number
of potential beneficial immunomodulating effects of beta-
blockers [15,24]. Moreover, the rate of cardiovascular
complications is high among intensive care unit (ICU)
patients [25,26], and a large proportion have cardiovascu-
lar comorbidities.
For these reasons preadmission beta-blocker use may
be associated with improved prognosis among ICU
patients. At the same time, however, beta-blocker use
may have detrimental effects in patients who need beta-
stimulation to maintain adequate tissue perfusion.
Virtually no data exist on the association between
beta-blocker use and mortality among general ICU
patients. We, thus, examined whether preadmission
beta-blocker use was associated with mortality within 30
days of ICU admission.
Materials and methods
Setting
We conducted this cohort study based on prospectively
collected data obtained from population-based medical
databases in northern Denmark. The study population
consisted of all patients admitted for the first time to an
ICU in one of three hospitals within the Aarhus Univer-
sity Hospital network during the study period. The ICUs
are highly specialized multidisciplinary tertiary units ser-
ving as both primary and referral ICUs, and together
they cover all major medical specialties. The nurse-to-
patient ratio is 1:1. For study purposes, two different
data collection periods were defined based on the initial
availability of computerized ICU data records: 1 January
1999 to 31 December 2005 for patients treated in Aar-
hus and Skejby Hospitals, and 1 January 2001 to 31
December 2005 for patients treated in Aalborg Hospital.
Since 1968 every Danish citizen has received at birth a
unique civil registration number from the Danish Civil
Registration System. This number permits accurate link-
age across all Danish registries.
ICU patients
A research database at the University of Aarhus contains
data on all admissions to the ICUs at Aarhus, Aalborg
and Skejby hospitals, including patient civil registration
numbers, dates of ICU admission and discharge, use of
mechanical ventilation, and use of renal replacement
therapy. We did not include patients who were admitted
for planned postoperative observation of less than
24 hours. Patients younger than 45 years of age were
also not included because beta-blockers are rarely pre-
scribed to persons in this age group in Denmark. Thus
9,515 ICU patients remained for further analysis. Only
patients with complete laboratory data were included in
the main analysis. The study cohort thus encompassed
8,087 eligible ICU patients with a first ICU admission
during the study period (85% of the entire cohort).
Preadmission use of beta-blockers
We collected data on all prescriptions filled by study
patients since 1997 from a prescription database that
contains data, transferred electronically from all phar-
macies in the region, on customers’ civil registration
numbers, types and dosages of drugs prescribed, and
redemption dates [27]. We defined current beta-blocker
use as at least one filled prescription within 125 days
before ICU admission. The 125-day period allowed us
to capture most current beta-blocker use, because few
beta-blocker prescriptions are expected to last more
than 125 days in Denmark. In a sensitivity analysis we
redefined current use as redemption of at least one pre-
scription within 60 days before ICU admission. Since
including prevalent use in the analysis could introduce
bias, we also defined subgroups of “new” and “long-
term” current beta-blocker users. “New” users had filled
their first-ever beta-blocker prescription within 125 days
of ICU admission, and “long-term” users had filled their
first-ever prescription more than 125 days before ICU
admission [28]. We also categorized patients according
to the type of the last beta-blocker prescribed before
ICU admission (that is, non-selective (Anatomical Ther-
apeutic Chemical (ATC)-codes: ‘C07AA02’ ‘C07AA03’
‘C07AA05’ ‘C07AA06’ ‘C07AA07’ ‘C07AA16’); non-
selective combined with alpha-adrenergic blocker (ATC
codes ‘C07AG01’ ‘C07AG02’); cardioselective (ATC
codes ‘C07AB02’ ‘C07AB03’ ‘C07AB04’ ‘C07AB05’
‘C07AB07’ ‘C07AB09’).
Other prognostic factors
We used the Danish National Patient Registry (DNPR)
to identify the primary diagnosis, that is, the diagnosis
listed first in the hospital registry record for the admis-
sion during which a patient was transferred to the ICU
[29]. On the basis of the primary diagnosis, patients
were grouped into eight disease categories: infectious
diseases; endocrinology (including diabetes); cardiovas-
cular diseases; respiratory diseases; gastrointestinal and
liver diseases; cancer; trauma and poisoning; and others.
We classified patients as ‘medical’ or ‘surgical’ according
to whether they had undergone any surgery within
seven days prior to ICU admission. To control for
comorbidity, we computed a Charlson Comorbidity
Index (CCI) score, based on a patient’s entire previous
hospital history since 1977. We defined three comorbid-
ity levels based on the CCI: low (score of 0), medium
(score of 1 to 2), and high (score ≥ 3) [30]. Alcoholism-
related disease was defined as either a previous hospital
diagnosis of an alcoholism-related disease (for example,
alcoholic liver disease) or redemption of a prescription
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for disulfiram. Through the DNPR we also obtained data
on use of temporary pacemakers, isoprenaline, vasopres-
sors, and inotropic drugs in 2004 and 2005. We
retrieved information on filled prescriptions for other
cardiovascular drugs including angiotensin-converting
enzyme (ACE-) inhibitors, statins and low-dose aspirin.
From hospital laboratory databases we obtained data on
the lowest hemoglobin measurement, the highest white
blood cell count (WBC), and the highest levels of C-
reactive protein (CRP) and creatinine registered within
two days before or after ICU admission. We were able
to retrieve all laboratory data for 8,087 patients (85% of
the entire cohort). We obtained data on urbanization
and marital status at the time of ICU admission from
the Danish Civil Registration System (CRS), as a mea-
sure of social status [31].
Mortality and migration data
To assess deaths and migration in our patient cohort,
we accessed data from the CRS [31]. The CRS contains
information for the entire Danish population on migra-
tion and changes in vital status, including exact date of
death, updated on a daily basis.
Statistical analysis
Follow-up began on the date of the first ICU admission
and continued until death, migration, or 30 days follow-
ing ICU admission, whichever came first. We computed
life table estimates for mortality within 30 days.
We used logistic regression to compute the odds ratio
(OR) of death for users of beta-blockers compared with
non-users, controlling for covariates listed in Table 1.
To assess the influence of excluding ICU patients with
missing laboratory data from the analysis, we repeated
the logistic regression model including all 9,515 ICU
patients, controlling for all covariates listed in Table 1,
except laboratory data.
For the propensity score analysis we generated a mul-
tivariable logistic regression model that predicted beta-
blocker use among ICU patients based on the covariate
profile listed in Table 1 and computed the propensity
score (that is, the probability of beta-blocker use) for all
ICU patients. Using a greedy matching algorithm, we
matched each beta-blocker user with the one non-user
with the closest propensity score, within a maximum
matching range of ± 0.025. In this manner we were able
to match each beta-blocker user to a non-user. Propen-
sity score matching decreased the absolute standardized
differences of each covariate to values below 0.1, indicat-
ing that an adequate balance was achieved. We used
conditional logistic regression to compute the odds ratio
(OR) as a measure of relative risk of death within 30
days after ICU admission for beta-blocker users com-
pared with non-users in the propensity score-matched
cohort. We conducted separate analyses for subgroups
defined according to admitting department, use of
mechanical ventilation, type of surgery, diagnostic cate-
gory, renal replacement therapy, use of selective vs.
non-selective beta-blockers, and new vs. long-term beta-
blocker use. We also repeated the propensity score-
matched analysis using conditional logistic regression
analysis to control for all covariates included in the
model. To assess possible unmeasured confounding by
indication for beta-blockers (primarily cardiovascular
diseases treated by general practitioners and thus not
registered in the DNPR), we restricted an analysis to
patients previously hospitalized with cardiovascular
diseases or diabetes. Finally, we repeated the propensity-
score-matched analysis after defining current beta-
blocker use as redemption of at least one prescription
within 60 days before ICU admission.
We calculated the biological interaction - or effect
measure modification - between statin and beta-blocker
use as the mortality in patients who used both statins
and beta-blockers, minus the mortality that statin use
adds, minus the mortality that beta-blocker use adds,
and minus the mortality in patients using neither beta-
blockers nor statins. We also conducted a propensity
score-matched analysis stratified by statin use.
All analyses were performed using SAS version 9.1.3
(SAS Institute Inc., Cary, NC, USA).
The study was approved by the Danish Data Protec-
tion Agency and the Aarhus University Hospital Registry
Board. Data were obtained from Danish registries, which
are generally available to researchers and their use does
not require informed consent.
Results
Descriptive data
Out of 8,087 ICU patients with complete laboratory data
available, 1,556 (19.2%) were current users of beta-
blockers upon ICU admission (Table 1). The most com-
monly used beta-blocker was metoprolol (n = 986
(63.4%)). Beta-blocker users were older than non-users
and had higher levels of comorbidity (43.1% of beta-
blocker users had a CCI score > 3 vs. 29.3% of non-
users). Compared with non-users, beta-blocker users
were admitted more often with cardiovascular diseases
and less often with cancer or following trauma/poison-
ing. As expected, beta-blocker users compared to non-
users were more often users of other cardiovascular
drugs including statins (30.1% vs. 6.4%), ACE-inhibitors
(40.7% vs. 14.6%), and low-dose aspirin (21.6% vs. 7.3%).
Propensity score matching balanced out these differ-
ences between the two groups (Table 1).
Among ICU patients admitted in 2004 and 2005, 24
(1.2%) beta-blocker users and 10 (1.8%) non-users were
treated with a temporary pacemaker. Isoprenaline was
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Table 1 Characteristics of ICU patients, Aarhus University Hospital, 1999 to 2005
Overall Propensity-score-matched cohorts
No current use of beta-
blockers
Current use of beta-
blockers
No current use of beta-
blockers
Current use of beta-
blockers
N (%) N (%) N (%) N (%)
Overall 6,531 (80.8%) 1,556 (19.2%) 1,556 (0%) 1,556 (100%)
Age group
46 to 59 2,100 (32.2%) 344 (22.1%) 307 (19.7%) 344 (22.1%)
60 to 75 2,880 (44.1%) 740 (47.6%) 790 (50.7%) 740 (47.6%)
75+ 1,551 (23.7%) 472 (30.3%) 459 (29.5%) 472 (30.3%)
Gender
Female 2,796 (42.8%) 598 (38.4%) 623 (40.0%) 598 (38.4%)
Male 3,735 (57.1%) 958 (61.6%) 933 (60.0%) 958 (61.6%)
Diagnostic category
Infectious disease 152 (2.3%) 37 (2.4%) 22 (1.4%) 37 (2.4%)
Cancer 1,200 (18.4%) 143 (9.2%) 114 (7.3%) 143 (9.2%)
Diabetes 88 (1.4%) 18 (1.2%) 14 (0.8%) 18 (1.2%)
Cardiovascular 1,812 (27.7%) 722 (46.4%) 756 (48.6%) 722 (46.4%)
Respiratory 753 (11.5%) 117 (7.5%) 103 (6.6%) 117 (7.5%)
Gastrointestinal 797 (12.2%) 176 (11.3%) 196 (12.6%) 176 (11.3%)
Trauma/poisoning 834 (12.8%) 137 (8.8%) 160 (10.3%) 137 (8.8%)
Other 895 (13.7%) 206 (13.2%) 191 (12.3%) 206 (13.2%)
Surgery within 7 days
No surgery 2,829 (43.3%) 611 (39.3%) 592 (38.1%) 611 (39.7%)
Surgery 3,702 (56.7%) 945 (60.7%) 964 (62.0%) 945 (60.7%)
Comorbidity
Charlson score
0 1,880 (28.8%) 237 (15.2%) 224 (14.4%) 237 (15.2%)
1 to 2 2,740 (42.0%) 649 (41.7%) 666 (42.8%) 649 (41.7%)
3 + 1,911 (29.3%) 670 (43.1%) 666 (42.8%) 670 (43.1%)
Alcoholism-related disorders 696 (10.7%) 160 (10.3%) 150 (9.6%) 160 (10.3%)
Preadmission drug use ACE-
inhibitors
954 (14.6%) 633 (40.7%) 644 (41.4%) 633 (40.7%)
Statins 415 (6.4%) 469 (30.1%) 436 (28.0%) 469 (30.1%)
Low-dose aspirin 477 (7.3%) 336 (21.6%) 311 (20.0%) 366 (21.6%)
Marital status
Married 2,729 (41.8%) 671 (43.1%) 652 (41.9%) 671 (43.1%)
Never married 476 (7.3%) 91 (5.7%) 88 (5.7%) 91 (5.9%)
Divorced 665 (10.2%) 128 (8.2%) 129 (8.3%) 128 (8.2%)
Widowed 910 (13.4%) 246 (15.8%) 243 (15.6%) 246 (15.8%)
Unknown 1,751 (26.8%) 420 (27.0%) 444 (28.5%) 420 (27.0%)
Laboratory data*
Hemoglobin
Low 3,049 (47.7%) 805 (51.8%) 771 (49.6%) 805 (51.7%)
High 3482 (53.4%) 751 (48.2%) 785 (50.4%) 751 (48.3%)
Leukocytes
Low 3,244 (49.7%) 787 (50.6%) 737 (47.4%) 787 (50.6%)
High 3,287 (50.3%) 769 (49.4%) 819 (52.6%) 769 (49.4%)
C-reactive protein
Low 3,318 (50.8%) 723 (46.8%) 703 (45.2%) 723 (46.8%)
High 3,213 (49.2%) 833 (53.2%) 453 (54.8%) 833 (53.2%)
Creatinine
Low 3,458 (53.0%) 577 (37.1%) 645 (41.5%) 577 (37.1%)
High 3,073 (47.1%) 979 (62.9%) 911 (58.6%) 979 (62.9%)
*Laboratory data were categorized into two groups based on median values.
Christensen et al. Critical Care 2011, 15:R87
http://ccforum.com/content/15/2/R87
Page 4 of 8
used for nine (0.4%) among beta-blocker uses and four
(0.7%) among non-users. Vasopressors and inotropic
drugs were used in 703 (36.5%) and 189 (9.3%) of beta-
blocker users vs. 211 (38.1%) and 59 (10.7%) of non-
users.
Mortality
Inclusion of all 8,087 ICU patients in a logistic regres-
sion analysis yielded an adjusted OR of 0.82 (95% CI:
0.71 to 0.94) for beta-blocker users compared with non-
users. In the propensity score-matched analysis of 1,556
beta-blocker users and 1,556 non-users, mortality was
25.7% among beta-blocker users and 31.4% among non-
users (corresponding to an OR of 0.74 (95% CI: 0.63 to
0.87)) (Figure 1).
Among users of non-selective beta-blockers, the esti-
mated OR was 0.99 (95% CI: 0.67 to 1.47); among users
of non-selective beta-blockers combined with alpha-
adrenergic blockers, the estimated OR was 0.66 (95% CI:
0.35 to .23); for users of cardioselective beta-blockers
the estimated OR was 0.70 (95% CI: 0.58 to 0.83). We
observed decreased ORs in most diagnostic categories,
Figure 1 Odds ratios (ORs) for death within 30 days after ICU admission among beta-blocker users vs. non-users. Type A: Non-selective
beta-blockers, Type B: non-selective beta-blockers combined with alpha-adrenergic blockers, type C: cardioselective beta-blockers).
Christensen et al. Critical Care 2011, 15:R87
http://ccforum.com/content/15/2/R87
Page 5 of 8
except for patients admitted with cancer or respiratory
diseases; however, the relatively small number of
patients in these categories resulted in risk estimates
with low statistical precision. Among patients treated
with invasive mechanical ventilation, the OR was 0.55
(95% CI: 0.41 to 0.75), and among those treated with
renal replacement therapy, the OR was 0.25 (95% CI:
0.05 to 1.28).Using a 60-day exposure window, rather
than a 125-day window, to define current beta-blocker
use yielded an OR of death of 0.74 (95% CI: 0.60 to
0.91). For new users, the OR of beta-blocker use was
0.57 (95% CI: 0.38 to 0.85) and for long-term users, the
OR of beta-blocker use was 0.78 (95% CI: 0.66 to 0.92).
When the analysis was restricted to patients with dia-
betes or cardiovascular comorbidities, the OR was 0.57
(95% CI: 0.44 to 0.74).
The biological interaction between beta-blocker and
statin uses was -11.7% (the mortality in beta-blocker
users who also used statins (21.7%), minus the estimated
25.4% mortality among those who used neither beta-
blockers nor statins, minus the estimated 0.6% (26.0%-
25.4%) mortality among statin-only users, minus the
estimated -5.8% (21.7%-27.5%) mortality among beta-
blocker users who died due to beta-blocker use). The
negative value suggests an additional beneficial effect -
that is, a mortality reducing effect - from combining
beta-blockers and statins. Like the analysis of absolute
mortality described above, the propensity score matched
analysis stratified by statin use also suggested that com-
bining statins and beta-blockers had an even further
beneficial mortality-reducing effect compared with beta-
blocker monotherapy (OR = 0.51 (95% CI: 0.35 to 0.73)
among beta-blocker users who also used statins vs. OR
= 0.89 (95% CI: 0.73 to 1.08)) among beta-blocker users
who did not use statins).
Discussion
In this cohort study we found that preadmission use of
beta-blockers was associated with reduced mortality
during the 30 days following ICU admission. To our
knowledge this is the first study of the association
between beta-blocker usage and mortality in general
ICU patients, although a number of studies have exam-
ined beta-blocker use in patients with specific diseases
or undergoing major surgery routinely requiring post-
operative ICU admission. Several studies reported that
beta-blocker use may reduce perioperative mortality in
patients undergoing major non-cardiac surgery, but no
earlier study provided separate data for ICU patients
[5,8,9,32].
In contrast with our findings, the POISE randomized
controlled trial reported that acute administration of
high-dose beta-blocker therapy perioperatively was asso-
ciated with reduced risk of myocardial infarction, but
increased risk of total mortality [10]. Of note, sepsis and
other infections were more common causes of death
among beta-blocker users than among non-users, while
there was no difference in risk of death due to multiple
organ failure, cardiogenic shock, or heart failure
between users and non-users. Less than 30% of POISE
participants were transferred to an ICU. In line with our
findings, a US observational study of 4,117 trauma
patients found that beta-blocker use was associated with
reduced in-hospital mortality [19]. The authors specu-
lated whether beta-blocker use led to attenuation of the
detrimental effects of hypermetabolism and increased
tissue oxygen consumption related to severe trauma.
Beta-blocker use has also been reported to have benefi-
cial effects in patients with severe burns, apparently by
decreasing energy expenditure and muscle catabolism
[18,20].
Our large population of general ICU patients per-
mitted robust estimates in a substantial number of pre-
defined patient categories. Use of prospectively recorded
data from independent medical databases with complete
follow-up limited the risk of selection, information and
surveillance biases. The completeness and nature of the
prescription database ensured that measurement of pre-
admission beta-blocker use was virtually complete [27].
Of note, changing the length of the period defining
exposure from 125 days to 60 days before ICU admis-
sion had virtually no impact on our risk estimates.
Thus, the influence of bias arising from misclassification
of beta-blocker use due to the length of the period
defining exposure as well as from unmeasured time bias
should be minor [33,34].
A potential study weakness is the lack of random
assignment of beta-blocker use, which may have intro-
duced confounding. Beta-blockers are prescribed for
cardiovascular diseases that may be associated with
increased mortality in ICU patients. Confounding arising
from underlying cardiovascular diseases, therefore,
would be most likely to attenuate our relative risk esti-
mates towards the null. Some patients with an indica-
tion for beta-blocker treatment may not have been
treated, for several reasons: because their condition was
undiagnosed, because treatment was stopped due to side
effects, or because of poor compliance. This potentially
could have influenced our results. We controlled for a
wide range of covariates using both propensity score-
matched analysis and logistic regression analysis. Beta-
blocker use was associated with reduced mortality in
analyses restricted both to patients with cardiovascular
comorbidities and to patients admitted with cardiovas-
cular diseases as the primary reason for hospitalization.
Thus, uncontrolled confounding by indications for beta-
blocker use is unlikely to explain our findings. Still, any
lack of specificity in routinely recorded data may have
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reduced our ability to completely remove confounding.
We lacked data on severity of illness, such as SAPS,
SOFA, or APACHE scores; however, laboratory data as
well as use of vasopressors and inotropics was virtually
the same among beta-blocker users and non-users. We
found consistent mortality reducing effects from beta-
blocker use in analysis restricted to ICU patients treated
with mechanical ventilation and renal replacement ther-
apy further indicating that confounding by severity of
disease seems unlikely to explain our findings.
Based on our study’s observational data we may only
speculate on the extent to which the immune-modulat-
ing effects, cardioprotective effects, and attenuation of
the hypermetabolic state of critical illness may explain
our findings. In asthma patients long-term beta-
blocker use has been reported to result in upregulation
of beta-receptors [35]. This may be beneficial in ICU
patients who require beta-stimulation to maintain ade-
quate tissue perfusion. Our results may, therefore,
not hold for patients who start taking beta-blockers
after getting severely ill. Of note, however, we found
slightly more pronounced mortality reductions in new
beta-blocker users compared with long-term users.
Still, since we had no data on in-hospital beta-blocker
use, we could not address the question of whether
beta-blocker use initiated immediately before ICU
admission is associated with mortality. The mortality
reducing effect of combining statins and beta-blockers,
that is, the biological interaction, could not solely be
explained by addition of the mortality reducing effect
of beta-blockers and statins. However, we know of no
biological mechanism explaining an additive beneficial
effect from combining statins and beta-blockers. Also,
since the study was not primarily designed to study
the interaction between statins and beta-blockers
potential confounding factors may not have been
included in the analysis and uncontrolled confounding
may thus have influenced the results. We do, however,
believe the risk to be minor. Still, it remains to be fully
elucidated whether an additional beneficial effect of
combining beta-blockers and statins, compared to
beta-blocker monotherapy, is a true biological effect.
Our data suggest that the beneficial effect of beta-
blocker use may be restricted to cardio-selective beta-
blockers. However, the relatively low number of
non-selective beta-blocker users produced statistically
imprecise mortality estimates, hindering any clear
interpretation of the results in these subgroups.
A concern is that some potentially beneficial effects of
beta-blockers in critically ill patients may be outweighed
by a decreased oxygen supply and decreased tissue per-
fusion associated with reduced cardiac output [21].
Another concern is the well-known side effects of beta-
blockade including severe hypotension and bradycardia;
however, in the present study the use of a temporary
pacemaker, isoprenaline as well as vasopressors and ino-
tropic drugs were virtually the same among beta-blocker
users and non-users. Although these data provide only a
rough measure of severe side effects of beta-blocker use,
they support the overall safety of this medication.
Conclusions
In conclusion, preadmission beta-blocker use is asso-
ciated with reduced 30-day mortality in general ICU
patients.
Key messages
• Beta-blocker use is associated with reduced risk of
death within 30 days in general ICU patients.
• The mortality reducing effect was similar among
medical and surgical ICU patients and was not
restricted to patients admitted with cardiovascular
diseases.
• It remains to be fully elucidated whether an addi-
tional beneficial effect of combining beta-blockers
and statins, compared to beta-blocker monotherapy,
is a true pharmacological effect.
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